Hypoalbuminemia, reported in 16% of patients treated with tepotinib, 23% with savolitinib, and 27% with amivantamab monotherapy,40,43 is a class effect of MET inhibition.74 It is also a marker of inflammation and an important prognostic factor in advanced NSCLC, as declining albumin levels can occur in the setting of increased active disease burden.75,76. This evidence concerns the gene ALB and Hypoalbuminemia.